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Abstract
Background. ABO incompatible kidney transplantation
using antigen-specific immunoadsorption is increasingly
performed but data on outcome, complications and proto-
col biopsies are still scarce. The present prospective single-
centre study was aimed at these issues.
Methods.This was a prospective single-centre cohort study
of 10 successive ABO incompatible living donor kid-
ney transplantations at the University Hospital Basel from
September 2005 to October 2007. The following param-
eters were closely monitored during the whole follow-up:
graft function, albuminuria, blood group antibody titres,
CD19+ cell count, total IgG and IgG subclasses, CMV
antigenaemia, decoy cells in the urine, EBV and polyoma
BK virus PCR in the blood. Protocol biopsies were per-
formed on Days 0 and 7 after 3, 6, 12 and 18 months.
Results. Patient and graft survival is 100% after a me-
dian follow-up of 489 days (range 183–916 days). Median
serum creatinine is 137 µmol/l (range 70–215 µmol/l), and
median urine albumin–creatinine ratio (UACR) is 3.1 mg/
mmol (range 0.6–7.8 mg/mmol) at the time of the last
follow-up. All patients had sustained diminished CD19+
cell count and/or total IgG concentrations. Neither CMV
antigenaemia nor EBV replication in the blood was ob-
served. Seven patients had positive polyoma BK virus
replication in the blood but none developed polyoma virus-
associated nephropathy (PVAN). Protocol biopsies revealed
rejection Banff IIa in three patients on Day 7, and in one
patient after 3 and 6 months. Banff Ia rejection was found
in five patients. All rejection episodes resolved. Mild signs
of chronic antibody-mediated rejection were observed in
five patients.
Conclusions. ABO-incompatible kidney transplantation
seems to be successful and safe. Modifications of the cur-
rent protocol may be possible and may further reduce po-
tential side effects and costs.
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Introduction
The persistent shortage of deceased organ donors and the in-
creasing number of patients waiting for a kidney transplant
necessitate new solutions to expand the pool of potential
kidney donors. Transplantation across blood group barri-
ers has been performed since the pioneering work of G.P.J.
Alexandre in the 1980s [1,2] and can increase the num-
ber of living donated kidney transplantations by at least
10% [3]. Recent studies using preconditioning regimens
with anti-CD20 antibodies, immune globulins and removal
of circulating blood group antibodies by plasmapheresis
(PP) or selective immunoadsorption (IA) revealed similar
short- and long-term patient and graft survival as observed
in blood group-compatible transplantation [4–8]. There-
fore, ABO-incompatible living donor kidney transplanta-
tion offers a promising strategy to reduce the number of
patients waiting for a kidney transplant, yet the current
experience in this field is still small. The present study
summarizes a prospective single-centre experience of ABO
blood group incompatible kidney transplantation at the
University Hospital Basel.
Methods
The principles of ABO blood group incompatible kidney
transplantation have been discussed in detail in two land-
mark publications [5,8].
Preparation and desensitization
In short, basic immunosuppressive therapy including
tacrolimus [0.1 mg/kg body weight (BW) twice daily], my-
cophenolate mofetil (1000 mg twice daily, 500 mg twice
C© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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daily if BW was <50 kg) and prednisone (30 mg once
daily) was started 2 weeks prior to transplantation. A single
dose of rituximab (375 mg/m2) was given 4 weeks prior
to transplantation in an outpatient setting. Selective blood
group antibody removal [selective immunoadsorption (IA)]
was performed with a low-molecular carbohydrate col-
umn containing A or B blood group antigens linked to a
sepharose matrix (Glycosorb R©, Glycorex Transplantation,
Lund, Sweden). Apheresis sessions were performed daily
until the immunoglobulin (IgG) and isoagglutinine (IgM)
antibody titres against donor erythrocytes were 1:8 or less,
as determined by the indirect Coombs test for IgG and the
saline method for IgM. The transplantation was then car-
ried out the following day. If one of the two titres remained
>1:8, additional IA was mandatory until the target titre was
achieved. With each session, two plasma volumes, calcu-
lated with the formula of Kaplan [9], were processed. After
the last IA, a single dose of intravenous (iv) immune globu-
lins (IVIG, 0.5 g/kg BW) on Day-1 and an additional T-cell
blockade with basiliximab 20 mg iv on Days 0 and 4 were
administered.
Follow-up
After transplantation, blood group IgM and IgG antibod-
ies against the donor blood group were measured daily for
2 weeks, weekly until Day 31, and then 3, 6 and 12 months
thereafter. Another three prophylactic IA were performed
on Days 2, 5 and 8, with one plasma volume processed each
time. From patient 8 on, regular prophylactic IA after kid-
ney transplantation was discontinued if the clinical course
was uneventful and the protocol biopsy on Day 7 revealed
no signs of antibody-mediated rejection. Target tacrolimus
trough levels were 10–12 ng/ml from Day 14 to 31, 8–
10 ng/ml from Day 32 to 90, 6–8 ng/ml from Day 91 to 365
and 4–6 ng/ml thereafter. Target mycophenolate mofetil
trough level was >2 mg/ml. Steroids [methylprednisolone
iv and prednisone perorally (po)] were tapered: 500 mg iv
onDay 0, 250mg iv onDay 1, 100mg iv onDay 2, 50mg po
fromDay 3 to 6, 0.5 mg/kg BWpo fromDay 7with a reduc-
tion by 5 mg every 2 weeks until 15 mg/day, then by 2.5 mg
every 2 weeks until a maintenance dose of 0.1 mg/kg BW
po was achieved. Primary prophylaxis with valganciclovir
in cases with a high risk of CMV infection (donor CMV
positive and/or recipient CMV positive) was performed
during 3months. Trimethoprim/sulfamethoxazol was given
three times weekly for 6 months as a primary prophylaxis
against Pneumocystis jiroveci pneumonia. Regular, at least
monthly viral screening was done for Epstein–Barr virus
(EBV; PCR), polyoma BK virus (BKV; PCR, decoy cells
in the urine) and cytomegalovirus (CMV; estimation of the
pp65 antigenaemia). The urine albumin to creatinine ratio
(UACR; enzymatic quantification, normal value<2.26mg/
mmol), a marker of glomerular injury, was measured be-
fore transplantation, on Days 7 and 14, in months 1, 2, 3,
4, 5, 6, 9, 12, and annually thereafter. CD19+ cell count,
total IgG concentration and IgG subclasses 1–4 were mea-
sured in the blood before rituximab therapy, the day before
transplantation, in months 1, 6, 12 and annually thereafter.
Protocol biopsies were taken on the day of transplantation
(‘zero biopsy’, taken 45–60 min after the start of reper-
fusion), after 1 week, and after 3, 6 and 12 months. In
general, two needle biopsy cores were obtained for mor-
phologic work-up and processed as previously described
elsewhere [10,11]. Electron microscopy was routinely per-
formed in all specimens. Biopsies were judged according
to the revised Banff criteria 2003 and 2005 [12,13]. All
complications were prospectively recorded at each clinical
visit.
Results
Patient characteristics
Between September 2005 and October 2007, 11 patients
were enrolled and prepared for transplantation according
to the protocol. One patient discontinued the preparation
because of an acute stress disorder. The remaining 10 pa-
tients were successfully transplanted. As of 1 April 2008,
patient and graft survival was 100% after a median follow-
up of 489 days (range 183–916 days). Donor and recipient
characteristics are shown in Table 1. All recipients’ EBV
serology was positive for IgG prior to transplantation. Two
patients had a CMV high-risk constellation (donor CMV
seropositive, recipient CMV seronegative), the recipient
was CMV positive in three cases and both donor and recip-
ient were CMV negative in five cases. The median number
of HLA A, HLA B and HLA DR mismatches was 5 (range
4–6). No recipient had donor-specific HLA antibodies be-
fore transplantation as measured by single antigen beads
on a luminex platform. The recipients’ anti-A- or anti-B-
IgM and IgG antibody titres against the donor blood group
(donor erythrocytes) before start of the preparation and the
total number of IA needed to achieve titres ≤1:8 are shown
in Table 1. One patient (case 2) experienced symptomatic
hypotension and bronchial obstruction a few minutes after
the start of the first IA, probably due to continued therapy
with an ACE inhibitor. IA was therefore replaced by total
plasma exchange treatments.
Posttransplant follow-up
The follow-up data are shown in Table 2. All 10 recip-
ients had immediate graft function after transplantation.
Early posttransplant follow-up was uneventful in 8 out of
10 patients. Our first patient experienced biopsy-proven
humoral rejection 13 days after transplantation. He was
successfully treated with anti-thymocyte globulins (ATG
Fresenius R©, 4 mg/kg BW) and IVIG (0.4 g/kg BW) for
7 days, three additional IA and five PP sessions. One
patient (case 4) has persistent, markedly elevated creati-
nine levels as a consequence of multiple operations due
to recurrent ureter leakage and obstruction as well as
recurrent bacterial pyelonephritis with graft injury. All
10 patients showed a rapid decline of UACR over time. Me-
dian UACR after 7 days was 29 mg/mmol (n = 9, range 9–
658 mg/mmol), 6 mg/mmol after 3 months (n = 10, range
1–39 mg/mmol), 5 mg/mmol after 6 months (n = 8, range
1–27 mg/mmol) and 4 mg/mmol after 12 months (n = 6,
range 1–25 mg/mmol). Table 2 shows the most recently
measured UACR of each patient.
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Table 1. Donor and recipient characteristics
Donor Recipient
Sex age BG BG Sex Age Relationship Original kidney
disease
Time on waiting
list (years)
Initial BG
antibody titres
IgM IgG
Number of IA
needed before
and after
transplantation
1 F 59 B → A1 M 47 Partner DN Pre-emptive 1:64 4
1:8 6 + 5 PP
2 F 43 AB→ B M 48 Partner IgA-N 3.3 1:16 4 (PP)
– 2 (PP)
3 M 28 A1 → 0 M 51 Brother-in-law PKD 3.9 1:128 11
1:256 3
4 F 66 A1 → 0 M 67 Partner IgA-N Pre-emptive 1:64 5
1:64 1
5 M 40 A1 → 0 M 40 Friend IgA-N 4.0 1:16 5
1:64 2
6 M 36 A1 → 0 F 34 Partner PKD Pre-emptive 1:32 4
1:32 2
7 F 42 A1 → 0 M 54 Sister PKD 1.7 1:256 16
1:256 1
8 F 61 A1 → 0 M 70 Friend GS 0.7 1:2 4
1:8 0
9 F 55 A1 → 0 M 55 Partner CIN 4.9 1:128 13
1:1024 0
10 M 73 A1 → B F 69 Partner DN 0.8 – 4
1:32 0
BG: blood group;DN: diabetic nephropathy; IgA-N: IgA-nephropathy;GS: glomerulosclerosis; PKD: polycystic kidney disease; CIN: chronic interstitial
nephritis; PP: plasmapheresis.
Table 2. Follow-up data
Patient Follow-up
(day)
Last creatinine
(µmol/l)
Last UACR
(mg/mmol)
Last aMDRD
(ml/min/
BKV Complications
1.73 m2)
1 916 125 4.1 53 +
2 747 98 1.6 70 +
3 729 153 5.4 42 + Deep venous thrombosis after
travelling
4 526 207 4.1 30 − 6 × surgical revision due to ureter
leakage,
2 × transplant pyelonephritis cataract
operation
5 505 143 0.6 47 +
6 489 84 1.2 67 +
7 376 131 1.1 52 − 2× transplant pyelonephritis
8 273 148 7.8 41 +
9 229 215 2.0 28 + Lymphocele operation; nephrectomy
(own kidney: infected kidney
stones with recurrent urinary tract
infection); herpes zoster
10 183 70 5.1 72 −
Median 489 137 3.1 50
Range 183–916 70–215 0.6–7.8 28–72
UACR: urine albumin creatinine ratio (normal value: <2.26 mg/mmol); aMDRD: calculation of glomerular filtration rate by the abbreviated MDRD
formula [14]; BKV: polyoma BK PCR in the blood.
Complications during follow-up
The complications of each patient are shown in Table 2.
Thus far, no CMV reactivation (positive p-65 antige-
naemia), CMV disease or EBV replication in the blood
has been observed. BKV replication in the blood was found
in seven patients (see Table 2): first positive PCR results
were seen after 7, 8, 11, 37, 46, 49 and 108 weeks (median
37 weeks), respectively. None of these patients had signs
of a polyoma virus-associated nephropathy (PVAN) in the
protocol biopsies following the positive BKV replication in
the blood.
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Table 3. Acute and chronic histological findings in protocol biopsies according to the Banff classification [12,13]; relevant acute lesions are highlighted
Patient Histological findings Zero-biopsy Day 7 Month 3 Month 6 Month 12 Month 18
1 Acute lesions N IIA N N N IA
Chronic lesions N N N N N Mild IF/TA
2 Acute lesions N N IA N N Not done
Chronic lesions N N N N N Not done
3 Acute lesions N N IIA IIA N N
Chronic lesions N N N N N Mild IF/TA
4 Acute lesions Ins. mat. Ins. mat. PN PN; IIA N –
Chronic lesions Ins. mat. Ins. mat. N Mild IF/TA Mild IF/TA –
5 Acute lesions N IIA N N N –
Chronic lesions N N N N N –
6 Acute lesions N N N N N –
Chronic lesions N N N N N –
7 Acute lesions N N IA IA – –
Chronic lesions N N Mild IF/TA Mild IF/TA – –
8 Acute lesions Not done N CNI IB – –
Chronic lesions Not done N N N – –
9 Acute lesions N IIA IA IA – –
Chronic lesions N N N Mild IF/TA – –
10 Acute lesions N N N – – –
Chronic lesions N N N – – –
N: normal; CNI: calcineurin inhibitor toxicity; PN: pyelonephritis; IF/TA: interstitial fibrosis and tubular atrophy; Ins. mat.: insufficient material; IA:
immunoadsorption.
Immunological follow-up data
IgM and IgG antibody titres against the donor blood group
remained below 1:8 during the entire follow-up period, with
only one exception (patient 8, IgG titre 1:16 after 1 month).
A strong and sustained suppression of CD19+ cells, which
represent the B-lymphocyte subpopulation, by a single dose
of rituximab and mycophenolate mofetil was found. The
mean CD19+ cell count in 9 out of 10 patients before ap-
plication of rituximab was 96/µl (n = 9, median 63/µl,
range 40–233/µl). One day before transplantation, median
CD19+ cell count was as low as 5/µl (n = 9, range 0–
9/µl), which was still found almost unchanged 1 month
after transplantation (n = 7, median 2/µl, range 0–16/µl).
Over time, the CD19+ cell count rose slightly to a median
12/µl after 6 months (n = 7, range 5–17/µl) and 25/µl af-
ter 12 months (n = 5, range 2–32/µl), respectively. Still,
this number is far below the initial cell count and below
the lower limit in normal controls (200–400/µl). Patient
8 suffers from chronic lymphatic leukaemia: in this case,
we found an extraordinarily high CD19+ cell count before
transplantation (7219/µl); during the follow-up, the num-
ber of CD19+ cells declined stepwise, with the last mea-
sured value of 966/µl (13% of pre-treatment value) after
7 months. IgG levels in the blood before rituximab treat-
mentwerewithin or above the normal range (n= 10,median
11.3 g/l, range 8.2–20.4 g/l, normal range 6.5–15 g/l) in all
patients. One month after transplantation, four out of eight
IgG levels were below the lower limit (n= 8,median 6.0 g/l,
range 4.6–11.7 g/l). After 6 and 12 months, total IgG levels
were below the lower limit in five and two patients, respec-
tively (6 months: n = 9, median 6.3 g/l, range 5.3–11.4 g/l,
12 months: n = 6, median 6.9 g/l, range 4.9–9.6 g/l).
Concerning IgG subclasses, no uniform pattern could be
found, with most patients having low quantities of IgG 1–4
throughout, in consistence with the reduced total amount
of IgG (data not shown).
Graft biopsies
The results of the protocol biopsies are shown in Table 3
(n= 46 including 2with insufficient material). All episodes
of acute interstitial or humoral rejection found in protocol
biopsies were treated with steroid pulse therapy. Patient 3,
who presented with a slight deterioration of graft function
at the time of his 3-month protocol biopsy, was additionally
treated with IVIG (0.4 g/kg BW) for 5 days. Six diagnostic
biopsies due to unexplained deterioration of graft function
were performed in three patients (patients 1, 4 and 9; two
biopsies each). The first diagnostic biopsy from patient 1
was performed within the first 2 weeks after transplantation
and revealed histological changes classified as Banff IB.
Another diagnostic biopsy after 14 months was performed
during steroid withdrawal: it revealed acute interstitial re-
jection Banff IA that was treated with steroid pulse therapy
and reintroduction of low dose prednisone. Patient 4 had
two diagnostic biopsies during the first month, one show-
ing signs of an acute humoral rejection (Banff IIA) that
was treated with IVIG (0.4 g/kg BW) for 5 days. A second
diagnostic biopsy showed no specific pathology. In patient
9, the two diagnostic biopsies (Days 18 and 41 posttrans-
plant) showed acute tubular necrosis in both samples. Zero
biopsies showed normal renal tissue with a negative C4d
immunostaining in all cases (n = 8). C4d immunostaining
became diffusely positive in all but one of the 36 follow-up
biopsies (one biopsy revealed only focal C4d positivity).
Discussion
The goal of ABO incompatible living donor kidney trans-
plantation is to increase the number of kidney transplan-
tations and to avoid or shorten the time on dialysis. The
rate of success and potential risks must be equal to those
after blood group-compatible transplantations. The present
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analysis shows a proof of concept. The number of living
donor kidney transplantations at the University Hospital
Basel has been increased by 20% (61 instead of 51) since
the start of the ABO incompatible program in September
2005. Four patients waiting >3 years for a graft could be
transplanted, and pre-emptive transplantation was possi-
ble in three cases. Seven patients with blood group O, the
blood group with the longest waiting time for a graft from
a deceased donor, were given the opportunity for transplan-
tation. In general, blood group O recipients (patients 3–9)
had higher blood group antibody titres, particularly IgG
titres, than patients with blood group A or B (patients 1,
2 and 10), and therefore needed a more intensive precon-
ditioning. Of note, all recipients with blood group O were
transplanted with an organ from a donor with blood group
A1. Patient and graft survival is excellent and does not differ
from blood group-compatible kidney transplantation. Even
patients with very high initial blood group antibody titres
(e.g. patient 9, IgG titre 1:1024) have been successfully
transplanted. Therefore, high initial anti-donor blood group
antibodies should not be an exclusion criterion for ABO in-
compatible transplantation as also shown by Donauer [7]
and Shimmura [15]. Regular IA posttransplant was per-
formed in our first seven patients as originally suggested
by Tyde´n [5]. Motivated by the results of Donauer [7], rou-
tine posttransplant IA was stopped in our last three patients
despite very high titres in one case (patient 9) without nega-
tive impact on A/B-antibody levels or renal function. These
results suggest that regular IA posttransplant in the absence
of clinical or histological evidence of graft dysfunction is
not needed. Markers of chronic graft injury, e.g. deterio-
ration of kidney function, albumin excretion in the urine
or chronic changes in the serial protocol biopsies, did not
increase over time despite persisting C4d positivity in all
graft biopsies. Hence, the relevance of C4d-positive graft
biopsies as a marker of acute or chronic humoral rejec-
tion differs between ABO-incompatible and donor-specific
anti-HLA antibody-positive grafts. We share the observa-
tion of Haas and colleagues [16] that C4d positivity in
ABO-incompatible grafts does not necessarily mean harm-
ful antibody-mediated rejection but has to be interpreted in
the context of additional clinical, histological and labora-
tory findings.
The spectrum of adverse events in the present analysis
is comparable with ABO-compatible kidney transplanta-
tion. Major complications that required re- or prolonged
hospitalization were due to surgical reasons and were un-
related to ABO incompatibility or its treatment. None of
the patients experienced CMV disease, CMV antigenaemia
or EBV replication. These findings suggest that the cur-
rent protocol does not carry an enhanced risk of over-
immunosuppression. Nevertheless, 7 out of 10 patients ex-
perienced repeatedly positive BKV replication in the blood
that did not proceed to overt BKV nephropathy probably
because of rapid lowering of the maintenance immunosup-
pression and subsequent disappearance of the virus in the
blood. The onset of BKV replication in the blood and the
occurrence of BKV nephropathy can correlate with the to-
tal amount of applied immunosuppression [17]. Patients
getting an ABO-incompatible graft are additionally treated
with rituximab. Therefore, it can be speculated that the
high number of patients showing BKV replication in this
study might be caused by this additional immunosuppres-
sant. Still, the balancing act of adequate immunosuppres-
sion remains a challenge. Of note is the highly significant
and sustained suppression of CD19 + B cells after a single
dose of rituximab and mycophenolate mofetil as already
shown by Genberg and colleagues [18]. B-cell depletion,
likely supported by therapy with mycophenolate mofetil,
led to a decrease of total IgG levels and its subclasses in the
blood.Although not clinically relevant until now, these find-
ings deserve long-term evaluation and raise the question of
whether rituximab is really necessary. Recently, successful
ABO incompatible transplantationwithout use of rituximab
or splenectomy has been published [19]. Therefore, this is-
sue needs further investigation as well as the usefulness
of single dose IVIG therapy immediately before transplan-
tation. The last patient to receive an ABO-incompatible
kidney transplant at our centre (data not shown) experi-
enced an anaphylactic reaction to IVIG immediately after
the infusion began. IVIG was discontinued, nevertheless
the patient received a kidney transplant the following day
with an uneventful follow-up. Hence, IVIG may be safely
withdrawn from the current protocol.
In conclusion, ABO-incompatible kidney transplantation
has become a standard procedure at our centre with an equal
success rate and adverse event profile as a blood group-
compatible transplantation. The number of living donor
kidney transplants could be increased by 20%. The rapidly
rising experience in this field, preferably gained by random-
ized controlled studies, may lead to further simplifications
of the currently used protocols. This will help reduce po-
tential side effects, lower costs and propagate this concept.
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